Human Recombinant CDKL4 protein, GST Tag (V2LY-0526-LY3068)

Li, Q., Chen, L., Ma, Y. F., Jian, X. E., Ji, J. H., You, W. W., & Zhao, P. L. (2021). Development of pteridin-7 (8H)-one analogues as highly potent cyclin-dependent kinase 4/6 inhibitors: Synthesis, structure-activity relationship, and biological activity. Bioorganic Chemistry, 116, 105324.

Assi, T., Kattan, J., Rassy, E., Nassereddine, H., Farhat, F., Honore, C., ... & Mir, O. (2020). Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. Critical Reviews in Oncology/Hematology, 153, 103029.

Wang, P. F., Qiu, H. Y., He, Y., & Zhu, H. L. (2020). Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015–2019). Expert Opinion on Therapeutic Patents, 30(10), 795-805.

Occhipinti, G., Romagnoli, E., Santoni, M., Cimadamore, A., Sorgentoni, G., Cecati, M., ... & Piva, F. (2020). Sequential or concomitant inhibition of cyclin-dependent kinase 4/6 before mTOR pathway in hormone-positive HER2 negative breast cancer: biological insights and clinical implications. Frontiers in genetics, 11, 349.

Guiley, K. Z., Stevenson, J. W., Lou, K., Barkovich, K. J., Kumarasamy, V., Wijeratne, T. U., ... & Rubin, S. M. (2019). p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science, 366(6471).

Vemu, B., Nauman, M. C., Veenstra, J. P., & Johnson, J. J. (2019). Structure activity relationship of xanthones for inhibition of Cyclin Dependent Kinase 4 from mangosteen (Garcinia mangostana L.). International journal of nutrition, 4(2), 38.

Zhou, Y., Shen, J. K., Yu, Z., Hornicek, F. J., Kan, Q., & Duan, Z. (2018). Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1864(5), 1573-1582.

Li, X., Seebacher, N. A., Garbutt, C., Ma, H., Gao, P., Xiao, T., ... & Duan, Z. (2018). Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. Cell death & disease, 9(5), 1-14.

Thill, M., & Schmidt, M. (2018). Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Therapeutic advances in medical oncology, 10, 1758835918793326.

Tripathy, D., Bardia, A., & Sellers, W. R. (2017). Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clinical Cancer Research, 23(13), 3251-3262.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols